| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4abf365daef6994a9f0c90909e424fe2 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D317-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C69-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-357
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C67-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C67-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D317-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C69-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C67-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-357
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D493-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C67-28 |
| filingDate |
2015-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5948ec8021a97c4eb62fe746ad02051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dde3f0f20c1c3cab85b6ea9d241dcd3a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f05118ac68a99368554ce4a651e3d84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b70f342428d38e76d808eb1034d9015 |
| publicationDate |
2017-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-106928063-A |
| titleOfInvention |
Ingenol Compounds and Their Application in Anti-HIV Latency Therapy |
| abstract |
The invention provides an ingenol compound and its application in anti-HIV latent treatment. Specifically, the present invention provides the use of ingenol compounds or pharmaceutically acceptable salts thereof, (a) intervening in HIV virus latency; (b) activating HIV virus integrated in mammalian genome; and/ Or (c) inducing expression of HIV provirus latent in infected cells. The combined use of the compound of the present invention and the antiretroviral drug can accelerate the clearance of the latent virus reservoir and help to improve the cure rate of AIDS. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110730771-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110730771-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11753363-B2 |
| priorityDate |
2015-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |